The psoriasis drug market is fiercely competitive, and strongly held by large pharmaceutical...
- Poxel closes enrolment in TIMES 2 trial of Imeglimin in Japan
- Cocrystal Pharma to study hepatitis C drug in Hong Kong
- Allergan assesses brazikumab in two clinical programmes for IBD
- Cardax doses first patient in CHASE trial for cardiovascular health drug
- Oxurion enrols first patient in Phase l trial of THR-687 for DME
GenSight Biologics reports positive data from REVERSE Phase III trial
GenSight Biologics has reported further results from its REVERSE Phase III clinical trial for the treatment of Leber hereditary optic neuropathy (LHON).
Novaliq reports positive results from ESSENCE trial of CyclASol 0.1%
Novaliq has reported positive topline results from its ESSENCE pivotal clinical trial designed to evaluate the efficacy, safety and tolerability of preservative-free ophthalmic solution CyclASol 0.1% to treat dry eye disease (DED).
AELIX Therapeutics and Gilead Sciences to trial HIV therapy
AELIX Therapeutics and Gilead Sciences have entered a joint clinical research collaboration for the analysis of proprietary investigational products.
Lumoxiti (Moxetumomab pasudotox –tdfk) for the Treatment of Hairy Cell Leukaemia
Lumoxiti (Moxetumomab pasudotox) is an investigational anti-CD22 recombinant immunotoxin developed as a potential treatment for relapsed/refractory hairy cell leukaemia (HCL) patients previously treated with at least two lines of therapy.
Abide Therapeutics starts Phase II trial of Tourette syndrome drug
Abide Therapeutics has started its Phase II clinical trial to examine the efficacy, safety, tolerability, and dosing regimen of ABX-1431 in treating Tourette syndrome (TS).
Galera Therapeutics doses first patient in Phase III trial of GC4419
Galera Therapeutics has dosed the first patient in a Phase III clinical trial of avasopasem manganese (GC4419).
ElectraSyn: A Potentiostat, Analytical Device and Stir Plate
In a unique endeavour, IKA's owner René Stiegelmann partnered with Professor Phil S Baran of Scripps Research Institute in La Jolia, California.
Aevi Genomic Medicine completes enrolment for Part B of ASCEND trial
Aevi Genomic Medicine has completed patient enrolment for Part B of its ASCEND clinical trial.
OncoSec starts Phase II trial of Tavo and Keytruda for TNBC
OncoSec Medical has started the Phase II KEYNOTE-890 clinical trial of Tavo for the treatment of late-stage triple negative breast cancer (TNBC).
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.